Logo image of AZYO

AZIYO BIOLOGICS INC-CLASS A (AZYO) Stock Fundamental Analysis

USA - NASDAQ:AZYO - US05479K1060 - Common Stock

1.49 USD
+0.03 (+2.05%)
Last: 9/6/2023, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, AZYO scores 1 out of 10 in our fundamental rating. AZYO was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of AZYO have multiple concerns. AZYO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AZYO had negative earnings in the past year.
AZYO had a negative operating cash flow in the past year.
In the past 5 years AZYO always reported negative net income.
AZYO had a negative operating cash flow in each of the past 5 years.
AZYO Yearly Net Income VS EBIT VS OCF VS FCFAZYO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

The profitability ratios for AZYO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AZYO Yearly ROA, ROE, ROICAZYO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 200 400 600

1.3 Margins

AZYO has a better Gross Margin (35.86%) than 75.90% of its industry peers.
In the last couple of years the Gross Margin of AZYO has declined.
The Profit Margin and Operating Margin are not available for AZYO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
AZYO Yearly Profit, Operating, Gross MarginsAZYO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

0

2. Health

2.1 Basic Checks

AZYO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZYO has been increased compared to 1 year ago.
The debt/assets ratio for AZYO is higher compared to a year ago.
AZYO Yearly Shares OutstandingAZYO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M
AZYO Yearly Total Debt VS Total AssetsAZYO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

AZYO has an Altman-Z score of -4.75. This is a bad value and indicates that AZYO is not financially healthy and even has some risk of bankruptcy.
AZYO's Altman-Z score of -4.75 is on the low side compared to the rest of the industry. AZYO is outperformed by 66.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.75
ROIC/WACCN/A
WACC16.57%
AZYO Yearly LT Debt VS Equity VS FCFAZYO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

AZYO has a Current Ratio of 0.84. This is a bad value and indicates that AZYO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.84, AZYO is not doing good in the industry: 92.99% of the companies in the same industry are doing better.
A Quick Ratio of 0.63 indicates that AZYO may have some problems paying its short term obligations.
AZYO has a worse Quick ratio (0.63) than 94.70% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.63
AZYO Yearly Current Assets VS Current LiabilitesAZYO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.95% over the past year.
Looking at the last year, AZYO shows a small growth in Revenue. The Revenue has grown by 4.13% in the last year.
The Revenue has been growing slightly by 4.66% on average over the past years.
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%

3.2 Future

The Earnings Per Share is expected to grow by 17.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.27% on average over the next years.
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZYO Yearly Revenue VS EstimatesAZYO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AZYO Yearly EPS VS EstimatesAZYO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AZYO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AZYO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AZYO Price Earnings VS Forward Price EarningsAZYO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZYO Per share dataAZYO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

AZYO's earnings are expected to grow with 17.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AZYO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZIYO BIOLOGICS INC-CLASS A

NASDAQ:AZYO (9/6/2023, 8:00:01 PM)

1.49

+0.03 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners74.28%
Inst Owner Change6.7%
Ins Owners3.94%
Ins Owner Change0%
Market Cap24.21M
Revenue(TTM)48.40M
Net Income(TTM)-33.95M
Analysts82.86
Price Target8.16 (447.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.35%
Min EPS beat(2)-119.74%
Max EPS beat(2)11.04%
EPS beat(4)2
Avg EPS beat(4)-17.6%
Min EPS beat(4)-119.74%
Max EPS beat(4)46.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.93%
Min Revenue beat(2)-19.25%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-7.19%
Min Revenue beat(4)-19.25%
Max Revenue beat(4)-1.06%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-133.33%
EPS NQ rev (3m)-55.56%
EPS NY rev (1m)-76.03%
EPS NY rev (3m)-33.12%
Revenue NQ rev (1m)48.44%
Revenue NQ rev (3m)-36.24%
Revenue NY rev (1m)12.37%
Revenue NY rev (3m)-27.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS2.98
BVpS-1.36
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.86%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
F-Score3
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.74%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.63
Altman-Z -4.75
F-Score3
WACC16.57%
ROIC/WACCN/A
Cap/Depr(3y)13.65%
Cap/Depr(5y)12.19%
Cap/Sales(3y)1.13%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.81%
OCF growth 3YN/A
OCF growth 5YN/A

AZIYO BIOLOGICS INC-CLASS A / AZYO FAQ

What is the fundamental rating for AZYO stock?

ChartMill assigns a fundamental rating of 1 / 10 to AZYO.


What is the valuation status of AZIYO BIOLOGICS INC-CLASS A (AZYO) stock?

ChartMill assigns a valuation rating of 1 / 10 to AZIYO BIOLOGICS INC-CLASS A (AZYO). This can be considered as Overvalued.


Can you provide the profitability details for AZIYO BIOLOGICS INC-CLASS A?

AZIYO BIOLOGICS INC-CLASS A (AZYO) has a profitability rating of 1 / 10.


How financially healthy is AZIYO BIOLOGICS INC-CLASS A?

The financial health rating of AZIYO BIOLOGICS INC-CLASS A (AZYO) is 0 / 10.